A trial announcement, a registry entry and a published paper can describe the same project while answering different questions. To evaluate a research claim, follow the documents and keep their roles separate.
Health Canada launched the Canadian Clinical Trial Search Portal on 29 July 2026, replacing its older Clinical Trials Database. The portal provides selected information and links to international registries; it is not a complete trial registry. Its initial coverage focuses on patient drug trials in phases 1-3 approved since 1 April 2013, with some phase classifications differing between systems. It does not include every kind of study.[1]
Four documents, four different questions
| Document | What to use it for |
|---|---|
| Canadian portal entry | Locate the Canadian trial record and its identifiers. |
| International registry record | Read the registered study design and outcome measures; look for dated changes and results. |
| Published paper | Examine what was actually analysed and reported, with its methods and limitations. |
| Canadian product information | Separately investigate authorization of a specific product for sale. A trial record cannot answer that question. |
Treat this as an evidence-tracing exercise. The aim is to make a claim easier to check, including the parts that remain uncertain.
Start with an identifier
Open Health Canada's clinical trial search portal and search a drug name, sponsor or protocol code. If you know the sponsor's protocol code, use it to narrow the search. The portal also offers filters such as condition, location, status and approval date. Open the trial title for details, then follow its registry link when available.[2]
Write down the protocol code, Health Canada control number and registry identifier before reading a summary. These are more useful for tracing a study than a promotional nickname.
Check the match before the claim
Compare the official protocol title, sponsor and protocol code with the linked registry record. Then check the study population and intervention. If the records disagree, investigate the mismatch before combining their details.
Health Canada notes that registry matching can produce errors, including when AI assists title matching. The official protocol title represents the trial Health Canada authorized. A convenient registry link is therefore a starting point, rather than a substitute for checking identifiers.[1]
Status is not a result
In the portal, closed can mean a trial ended normally or stopped early and will not restart. It does not mean the intervention succeeded. A completion date may be estimated or actual; it is not a publication date. An unknown status means the registry status has not been verified within the past two years.[3]
Missing information also needs restraint. Health Canada's portal guidance describes incomplete records and delays in obtaining registry information. If a results field is empty, record 'not located in this record on this date.' Do not convert that observation into 'no study exists' or 'the study failed.'[4]
Compare the planned outcome with the reported outcome
Find the primary outcome in the registry and the paper's methods. Compare its definition, assessment time and analysis population. Where available, consult dated registry versions, the protocol and amendments rather than relying solely on the latest entry.
A change is a question to investigate. Look for when it was made, why it was made and whether the paper explains it. An amendment may have a reasonable explanation; a discrepancy alone does not establish misconduct.
| Record in your notes | Compare across documents |
|---|---|
| Identity | Protocol code; registry identifier; sponsor; official title. |
| Chronology | Registration date; study dates; amendment dates; paper date. |
| Primary outcome | Exact measure; time point; analysis population. |
| Reported results | Where results appear; which outcome is emphasized; uncertainty. |
| Unresolved differences | The mismatch, possible explanation and document still needed. |
Hypothetical example: a record specifies an outcome at week 24, while a paper emphasizes a different measure at week 12. Flag both differences, then look for a dated amendment and the paper's explanation. Without those documents, leave the interpretation open.
This comparison worksheet is an editorial reading aid, not a formal research-quality score.
Why this document trail matters
Two original studies illustrate why registry-to-publication comparisons are useful. They studied reporting practices across trials, rather than the efficacy of any peptide.
Mathieu and colleagues, 2009: a cross-sectional audit examined 323 randomized trial reports published in 2008 across cardiology, rheumatology and gastroenterology. Of 147 trials meeting the authors' registration criteria, 46 (31.3%) had a discrepancy between registered and published primary outcomes. Those criteria allowed registration before trial completion; they should not be described as uniformly requiring registration before enrolment. The sample was historical and concentrated in selected high-impact journals.[5]
Chen and colleagues, 2019: a cross-sectional comparison of 389 randomized trials published in 2011-2015 found that 130 (33.4%) had at least one primary-outcome change between registration and publication. Its English-language, historical sample and incomplete or unavailable records limit generalization. The comparison does not establish why an outcome changed.[6]
Neither percentage estimates the reliability of today's peptide literature. The useful lesson is procedural: locate the registered outcome and check how the publication reports it. Read amendments and explanations before judging a difference.
Keep trial authorization separate from product authorization
An approved trial in the Canadian portal has met the requirements for that trial. It does not establish that a retail product is authorized for sale. Health Canada's participant guidance explains that only some drugs entering clinical trials eventually receive market authorization.[3][7]
For a separate product check, consult Health Canada's Drug Product Database, which contains drugs authorized for sale and is updated nightly. Match the actual product details; an ingredient name by itself does not identify the product under review.[8]
A certificate of analysis addresses the analytical information stated in that document. It does not establish authorization to market a product. Nor does a trial conducted on one formulation validate an unrelated vial or batch.
Leave a reproducible note
Finish with a short record: the claim you checked, the identifiers, the source links, the access date, what the documents support and what remains unresolved. Save the distinction between a planned outcome, a reported result and your interpretation.
A careful note might read: 'Registry and publication identifiers match. The primary-outcome time point differs. A dated explanation was not located in the documents reviewed on 8 October 2026.' That is more useful than a confidence label unsupported by the underlying records.
Related reading
For the broader distinctions, see PEPTIVIA's guide to cell studies, animal models and human trials. For paper-level appraisal, see population, comparator, endpoint and follow-up. For the separate Canadian product check, see research materials and authorized medicines in Canada.
References
- Health Canada: About the clinical trial portal. 28 July 2026. Official Canadian documentation, not a study. Selected coverage and registry matching limitations apply. Linked sources checked 8 October 2026.
- Health Canada: How to use the portal. 28 July 2026. Official Canadian documentation, not a study; search instructions do not establish trial results. Linked sources checked 8 October 2026.
- Health Canada: Portal definitions. 28 July 2026. Official Canadian documentation, not a study; status and dates are not efficacy findings. Linked sources checked 8 October 2026.
- Health Canada: Portal guidance. 28 July 2026. Official Canadian documentation, not a study; incomplete records and registry-information delays limit interpretation. Linked sources checked 8 October 2026.
- Mathieu et al. Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials. 2 September 2009. Original peer-reviewed cross-sectional meta-research, not peptide efficacy research. Historical selected high-impact-journal sample; registration criteria allowed registration before trial completion, not uniformly before enrolment. Correction 14 October 2009 (doi:10.1001/jama.2009.1433) does not change the cited 46/147 result. Linked sources checked 8 October 2026.
- Chen et al. Comparison of Clinical Trial Changes in Primary Outcome and Reported Intervention Effect Size Between Trial Registration and Publication. 19 July 2019. Original peer-reviewed cross-sectional meta-research, not peptide efficacy research. Historical English-language sample and incomplete/unavailable records limit generalization; differences do not establish why outcomes changed. Linked sources checked 8 October 2026.
- Health Canada: Information for potential expanded-access trial participants. 29 September 2025. Official Canadian documentation, not a study; trial participation is separate from market authorization. Linked sources checked 8 October 2026.
- Health Canada: Drug Product Database. 18 June 2015; database updated nightly. Official Canadian documentation, not a study; match actual product details, not ingredient name alone. Linked sources checked 8 October 2026.
Owner-provided references describe the studied materials and official guidance, not PEPTIVIA batches, product equivalence, safety or authorization. No independent expert review is claimed.